Aussies & Kiwis with incurable blood cancer receive newly subsidised treatment option

Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…

Read More

Communicating with personnel during the COVID-19 pandemic

Our own VIVA! Communications Principal and owner, Kirsten Bruce, Sydney was quoted in pharmaceutical industry publication, Pharma in Focus today on how to engage with staff working from home during the current COVID-19 pandemic. She cited the importance of corporate messaging being “clear, concise and reassuring to their employees, customers and stakeholders alike, explaining that…

Read More

1 in 10 Aussies with epilepsy sustaining serious physical injuries

VIVA! Communications is delighted to be teaming with UCB today (Thursday, March 26, 2020) to highlight the serious injuries caused by epileptic seizures, and call for heightened awareness, understanding and support for the 250,000 Australians living with epilepsy. One in 10 Australians living with epilepsy experience a seizure-related injury each year, many of which are…

Read More

Solution to the increasing demand for hospital beds

An aging population, proliferation of chronic disease and the rise of the informed patient are some of the key factors propelling a substantial increase in healthcare spending and demand for hospital beds across the developed world. Australia has more than 1,300 public and private hospitals, which collectively provide an estimated 30 million days of admitted…

Read More